Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Nilotinib

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No minimum purchase guarantees; actual demand depends on prescription behavior and may be low.

The buyer may terminate the procedure early if exclusive agreements are concluded, ending all non-exclusive agreements.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products containing Nilotinib (ATC L01EA03) to AOK PLUS insured members in Saxony and Thuringia
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Afficher le résumé complet

This tender is a non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active substance Nilotinib (ATC L01EA03), conducted as an Open-House model by AOK PLUS for Saxony and Thuringia. The procedure is voluntary transparency publication, not a formal procurement under EU directive. Any qualified pharmaceutical entrepreneur can join during the participation period. No guaranteed volumes, no exclusivity, and the agreement ends by 31 July 2027 unless terminated earlier due to exclusive agreements. The estimated value is not disclosed. Submission is electronic via DTVP portal; first deadline 7 July 2026, with subsequent periodic deadlines.

Risques

No minimum purchase guarantees; actual demand depends on prescription behavior and may be low.

The buyer may terminate the procedure early if exclusive agreements are concluded, ending all non-exclusive agreements.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered medicines

Eligibility

  • Must submit a self-declaration on exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit a self-declaration on Russia sanctions (Eigenerklärung Russlandsanktionen)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Price: The discount is the key criterion but not formally weighted; acceptance is based on meeting participation requirements and accepting the terms.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Nilotinib

Open-House model for concluding non-exclusive rebate agreements for Nilotinib (excluding Nilotinib dispersed in applesauce unless patent-protected). The agreement is open to all interested pharmaceutical entrepreneurs meeting the requirements. No minimum purchase quantities, no exclusivity. Contract ends by 31 July 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jul 2026 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Jul 31, 2027

Détails de la procédure

Date de publication
05 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
308469-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30